TCL Archive Guest Editorial: Even Slam-Dunk Applications Can Benefit From Public Scrutiny and Discussion at ODAC August 10, 2012
TCL Archive DCT Faces Hard Choices, Clinical Group Need Re-Examination, Chabner tells BSC November 12, 1982
TCL Archive In Brief: Fishman La Jolla President Emeritus, Ruoslahti Succeeds Him; Ariz. Seeks Meyskins Replacement January 13, 1989
TCL Archive FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says. January 14, 2005
